Design Therapeutics Inc (DSGN) - Total Liabilities
Based on the latest financial reports, Design Therapeutics Inc (DSGN) has total liabilities worth $12.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DSGN financial resilience to evaluate the company's liquid asset resilience ratio.
Design Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Design Therapeutics Inc.
Design Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Design Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yingkou Fengguang Advanced Material Co.Ltd.
SHE:301100
|
China | CN¥327.78 Million |
|
Shenmao Technology Inc
TW:3305
|
Taiwan | NT$6.84 Billion |
|
Tianjin Jinbin Development
SHE:000897
|
China | CN¥1.31 Billion |
|
Better Home & Finance Holding Company
NYSE:BETR
|
USA | $1.16 Billion |
|
Nantex Industry Co Ltd
TW:2108
|
Taiwan | NT$2.40 Billion |
|
Zhejiang HISUN Biomaterials Co. Ltd. A
SHG:688203
|
China | CN¥542.63 Million |
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
China | CN¥2.00 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥329.38 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Design Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Design Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Design Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Design Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Design Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.00 Million | -16.39% |
| 2023-12-31 | $11.96 Million | -13.53% |
| 2022-12-31 | $13.83 Million | +64.08% |
| 2021-12-31 | $8.43 Million | -82.38% |
| 2020-12-31 | $47.83 Million | +1181.65% |
| 2019-12-31 | $3.73 Million | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more